Grace Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-7.8M | $-9.6M | $-12.9M | $-42.4M | $-9.8M | $-19.7M | $-25.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | $7.0K | $7.0K | $11.0K | $124.0K | $0 | $143.0K | $410.0K |
| Amortization | — | — | — | — | $0 | $781.0K | $1.9M |
| Stock-Based Compensation | $798.0K | $730.0K | $913.0K | $1.8M | $1.3M | $1.2M | $2.0M |
| Net Cash from Operating Activities | $-8.9M | $-14.9M | $-12.3M | $-15.9M | $-17.2M | $-14.3M | $-23.0M |
| Investing Activities | |||||||
| Capital Expenditures | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $0 | $104.0K | $13.2M | $-3.5M | $-9.9M | $8.1M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.7M | $14.0M | $7.4M | $304.0K | $0 | $59.5M | $13.2M |
| Net Change in Cash | $-5.2M | $-872.0K | $-4.9M | $-2.5M | $-20.6M | $36.7M | $-2.6M |
| Free Cash Flow | — | — | — | — | — | — | — |